Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod PK interaction with Cyclosporine
NCT04149678Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 15 days, Area Under the Curve to Infinity at 15 days and 1 more. Started Oct 2019; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04149678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149678.